American Association for Cancer Research
00085472can160842-sup-164044_2_supp_3654505_vd0y4t.docx (35.99 kB)

Supplementary Materials and Methods from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Download (35.99 kB)
journal contribution
posted on 2023-03-31, 00:46 authored by Xiaohu Zheng, Xiaolei Fan, Binqing Fu, Meijuan Zheng, Aimei Zhang, Kai Zhong, Jialai Yan, Rui Sun, Zhigang Tian, Haiming Wei

Supplementary Materials and Methods including Antibody staining, clinical samples information, ADCC/ADCP, chemotherapeutic drug treatment, xenograft model establishing, cell sorting, colony formation and tumorigenicity, magnetic resonance imaging and bone immunofluorescence.


Natural Science Foundation of China

China Postdoctoral Science Foundation



The lack of effective tumor-associated antigens restricts the development of targeted therapies against myeloid leukemia. In this study, we compared gene expression patterns of acute myeloid leukemia (AML) and normal bone marrow samples and found that epithelial cell adhesion molecule (EpCAM) is frequently overexpressed in patients with AML, with EpCAM+ leukemic cells exhibiting enhanced chemoresistance and oncogenesis. The chemotherapeutic resistance of EpCAM-positive leukemic cells is a consequence of increased WNT5B signaling. Furthermore, we generated EpCAM antibodies that enabled phagocytosis or cytotoxicity of AML cells by macrophage or natural killer cells, respectively. Finally, EpCAM antibody treatment depleted AML in subcutaneous, disseminated, and intramedullary engrafted mice. In summary, EpCAM exhibits promise as a novel target for the treatment of leukemia. Cancer Res; 77(2); 482–93. ©2016 AACR.